Feb 4 2010
CanLiv: The Hepatobiliary Cancers Foundation in partnership with The
Cholangiocarcinoma Foundation will host the 1st Annual
Biliary Tract-Gallbladder Cancer Research Symposium on Friday, May 7,
2010 at the American Society of Clinical Oncologists (ASCO) headquarters
in Alexandria, Virginia.
“Treatment for all cancers requires a multi-disciplinary team”
The Symposium will engage scientists, clinical researchers, government
partners and the patient advocacy community from across the globe in
developing a strategic plan to accelerate clinical and translational
research to advance treatment of gallbladder and biliary tract cancers.
With a stated objective to work collaboratively, the Symposium will
assemble stakeholders in hepatobiliary cancer medicine to harness
wisdom, passion and ideas for designing a roadmap to accelerate research
and treatment of bile duct and gallbladder cancers. Registration is
open, please visit, www.canliv.org/invite.asp.
“Treatment for all cancers requires a multi-disciplinary team,” stated
Dr. Melanie B. Thomas, Associate Director of Clinical Investigations,
Hollings Cancer Center; Associate Professor, Grace E. DeWolff Chair in
Medical Oncology, Medical University of South Carolina and Symposium
Chair. “Although rare in the United States, biliary and gallbladder
cancers tumors affect many thousands of individuals worldwide. These
'orphan' tumors have few effective treatments as there is limited
research funding and public attention focused on them. To accelerate
research in hepatobiliary cancers, this Symposium will create an
inclusive community that will identify strategies to overcome
traditional medical research silos. My goal is that together, the
Symposium assembly will work collaboratively to design a roadmap to
improve the treatment options for patients with gallbladder and bile
duct cancers.”
The one-day Symposium will pre-assign multi-disciplinary “Research
Teams” to address four important areas: Key Knowledge Gaps in
Pre-Clinical Science; Building Effective Advocacy for Biliary Tract and
Gallbladder Cancer; Clinical Research - Promise and Possibilities; The
Way Forward - Designing the Roadmap to Accelerate Hepatobiliary Cancer
Treatment.
The Symposium agenda includes expert panel discussions, interactive
exchanges to facilitate cross-discipline learning and Research Team
group work. (Please see attached preliminary agenda)
CanLiv will award its inaugural 2010 Translational Research Grants at
the conclusion of the Symposium. The Symposium is offered with no
registration fee and registrants are encouraged to make a donation to
the CanLiv Foundation in lieu of a registration fee. Donations will be
used to fund the 2010 Translational Research Grants.
Source:
CanLiv: The Hepatobiliary Cancers Foundation